TP53 and cervical cancer: Our previous data demonstrated that dose-dependent declines in these p53, cyclin D1, and p21 proteins were detected when cells were treated with T. mongolicum and T. formosanum in one human cervical cancer cell line, i.e., HeLa cells [16].